ASCO 2026 Bladder Cancer

Viewing 1-20 of 47 articles

ASCO 2026: TROPION-Urothelial03: A Phase 2/3 Study of Datopotamab Deruxtecan + Platinum Based Chemotherapy versus Gemcitabine + Platinum Based Chemotherapy

ASCO 2026: Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized MIBC Patients: SASAN-SPARING Trial

ASCO 2026: Avelumab + Sacituzumab Govitecan versus Avelumab Monotherapy as First Line Maintenance Treatment for Advanced Urothelial Carcinoma: Updated Subgroup Analyses of JAVELIN Bladder Medley Based on Metastatic Sites

ASCO 2026: Neoadjuvant and Adjuvant (Neoadj-Adj) Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) in Participants with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (MIBC): An Analysis of Clinically Relevant Subgroups in KEYNOTE-905.

ASCO 2026: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Avelumab After First Line Platinum Based Chemotherapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (Alliance A032001)

ASCO 2026: Bulumtatug Fuvedotin + Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Follow-up Results from a Phase 1b/2 Study

ASCO 2026: Initial Results from EXCEED, a Phase 1 Study of LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma

ASCO 2026: Real-World Patterns and Clinical Outcomes Among US Patients with NMIBC During the BCG Shortage

ASCO 2026: Interim Analysis from Duravelo-2: Zelenectide Pevedotin + Pembrolizumab in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

ASCO 2026: Durvalumab in Combination with BCG Induction and Maintenance Therapy for BCG-Naïve, High Risk NMIBC: 5 Year Overall Survival Analysis and PROs from POTOMAC

ASCO 2026: Neoadjuvant Sacituzumab Govitecan in Patients with Muscle-Invasive Bladder Cancer: Final Results and Biomarker Analyses of the SURE-01 Trial

ASCO 2026: Magnitude and Timing of Clinical Benefit Associated with Pathological Complete Response in Perioperative MIBC: A Reconstructed IPD Analysis of NIAGARA Trial

ASCO 2026: Bulumtatug Fuvedotin (BFv; 9MW2821) + Toripalimab in Perioperative Patients with MIBC: Results of Cohort a from a Phase 2 Study

ASCO 2026: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Real-World Evidence from the SOGUG-NIADY Study of the Spanish Oncology Genitourinary Group (SOGUG)

ASCO 2026: Cost-Effectiveness Analysis of First-Line Therapies for Advanced Urothelial Carcinoma from a U.S. Payer Perspective.

ASCO 2026: Circulating Tumor DNA (ctDNA) Dynamics as Early Biomarkers of Response to Enfortumab Vedotin plus Pembrolizumab in Advanced Urothelial Carcinoma

ASCO 2026: Patient Experiences with UGN-102 for Recurrent Low Grade Intermediate Risk NMIBC: Insights for Shared Decision Making

ASCO 2026: Molecular Characterization of Residual Disease Post-Neoadjuvant Sacituzumab Govitecan, Pembrolizumab, or Their Combination in Patients with MIBC

ASCO 2026: UTOPIA: A Phase 3 Trial of UGN-103, an Intravesical Mitomycin Reverse Thermal Hydrogel, in Recurrent Low Grade Intermediate Risk NMIBC

ASCO 2026: Assessing Responses to UGN-102 Across EORTC Recurrence Score Groups in Patients with Recurrent Low Grade Intermediate Risk NMIBC (ENVISION Trial)

1
2
3